Prognostic values of inflammatory indexes in bevacizumab-treated patients with advanced non-small-cell lung cancer by Jingru Yang, Mingliang Deng, Minghong Bi, Yaping Wang, Xuxu Qiao, Shanshan Zhang

Get full text

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study by Dong Zhao, Minghong Bi, Xiaofei Cheng, Shuhong Wang, Huaidong Cheng, Xiaoyang Xia, Huan Chen, Yanbei Zhang, Zhiqiang Hu, Qisheng Cao, Hui Liang, Fan Wang, Xuhong Min, Ling Xu, Kehai Feng, Jinhua Zhou, Xinzhong Li, Rui Wang, Hua Xie, Xiaosi Chen, Kangsheng Gu

Get full text

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors by Mingchuan Zhao, Xichun Hu, Pengpeng Zhuang, Aiping Zeng, Yan Yu, Zhendong Chen, Hongmei Sun, Weihua Yang, Lili Sheng, Peijian Peng, Jingfen Wang, Tienan Yi, Minghong Bi, Huaqiu Shi, Mingli Ni, Xiumei Dai, Changlu Hu, Hongjie Xu, Dongqing Lv, Qingshan Li, Kaijian Lei, Xia Yuan, Ou Jiang, Xicheng Wang, Baihui Hu, Zhe Hou, Zhaoping Su, Song Zheng, Ming Zhou, Changlin Dou

Get full text

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lun... by Yuankai Shi, Minghong Bi, Qingshan Li, Guolei Wang, Jianhua Chen, Mingjun Li, Jianhua Shi, Jiazhuan Mei, Yinghua Ji, Qingdi Xia, Yuanqing Feng, Shufeng Xu, Tongmei Zhang, Xiaohui Gao, Shubin Tang, Jie Weng, Zhuo Cao, Hongbo Wu, Xiubao Ren, Hua Xie, Hua Liu, Qiang Liu, Xing Yin, Xiaoyong Luo, Jun Chen, Haiming Zhang, Zhiyuan Guo, Cuimin Ding, Xin Jin, Rongli Sun, Sheng Yang

Get full text